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NosocomialTransmissionofMultidrug-Resistant
Mycobacterium tuberculosis in Spain
Before 1990, outbreaks of multidrug-resistant
tuberculosis (MDRTB) were uncommon (1); since
then,more than 10 outbreaks have been reported,
all in hospitals and prisons in the eastern United
States (2-7). Persons traditionally considered at
risk for MDRTB (foreign-born TB patients and
those inadequately treated for TB) have not been
associatedwiththeseoutbreaks.Instead,thepres-
ence of patients with active TB near immunocom-
promised patients in HIV-dedicated wards has led
to MDRTB-infected HIV patients whose TB cases
often go unrecognized.The patients receive inade-
quate treatment in facilities without effective pro-
cedures for isolating acid-fast bacilli; these
circumstances favor nosocomial transmission.
Health officials in other geographic areas where
HIV and TB are major public health threats have
been alerted to this emerging problem, and sur-
veillance systems have been designed (8).
Spain has the highest reported incidence rate
ofAIDSinEurope(143.4casespermillionin1994)
(9). Although in Spain TB is not notifiable at the
national level, reported rates in the autonomous
community of Madrid for 1994 were among the
highest in Europe (33.5/100,000) (10). During a
45-month period starting in September 1991, a
number of patients and one health care worker
became infected with MDRTB in a 120-bed, infec-
tious disease reference hospital in urban Madrid.
In May 1995, the Field Epidemiology Training
Program of the Spanish Ministry of Health was
invitedto assistthe MadridDepartmentofHealth
and hospital officials in investigating the out-
break. This report describes the findings of the
epidemiologic and molecular laboratory investiga-
tion and analyzes risk factors associated with the
outbreak. The study was designed in three parts:
1) a description of the reported MDRTB cases,
including a laboratory investigation of isolates;
2) a case-control study comparing HIV-infected
patients who also had MDRTB to HIV-infected
patients who did not have MDRTB;and 3) a study
of tuberculin conversion among hospital employ-
ees.
We reviewed the medical records and labora-
toryspecimentestingresultsofaseriesofpatients
with MDRTB in the HIV-dedicated ward of the
hospital for January 1991 through June 1995.
Cases were defined as patients with culture-con-
firmed TB and drug resistance to atleastrifampin
and isoniazid and with no previous history of
inadequate treatment. Demographic and clinical
variableswerecollectedtocharacterizethecluster.
Drug susceptibility testing and DNA subtyping
analysis were performed with resistant strains
available at the time of the study. Drug suscepti-
bility testing was performed by the method of
proportionsinMiddlebrook7H11 medium distrib-
uted in petri plate compartments (reference).
All 48 reported cases of isoniazid and rifampin
resistance were among HIV-infected patients hos-
pitalized in the HIV-dedicated ward from Septem-
ber 15, 1991, to May 1995. One patient was an
HIV-infected nurse who worked on the ward from
1990 to 1994. The mean age of patients was 34.1;
81.3% were male, and 66.6% were intravenous-
drug users (Table 1). Of the 47 (97.9%) who died,
the mean interval from diagnosis to death was
77.6 days.
The epidemiologic curve suggests a propagated
transmissionpatternofMDRTBamongHIVward
patients, starting in 1991 and continuing until
June1995(Figure1).Bythefirst6monthsof1995,
65% of Mycobacterium tuberculosis strains seen
among HIV ward patients were multidrug-resis-
tant.
Table 1.MDRTB patient characteristics
Number
Variable (n = 48) %
Sex
Male 39 81.3
Female 9 18.7
Mean age 34.1 (6.8)
a
HIV status
Infected 48 100.0
HIV risk group
Intravenous drug users 32 66.6
Homosexual 10 20.8
Others 6 12.6
Outcome
Death 47 95.9
Discharge 1 4.1
Mean survival after 77.6 (107.8)
a
MDRTB diagnosis
(in days)
a Standard deviation.
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antibiogrampatternwasobservedamongisolates.
However, beginning in 1993, strains were consis-
tently resistant to isoniazid,streptomycin,etham-
butol, and rifampin (HSER); of the 26 patients
with an MDRTB diagnosis since the lasttrimester
of 1993, 24 (92.3%) had HSER isolates. DNA sub-
typing analysis was performed on 12 of these
HSER isolates that were available. Eleven of the
12 strains had the same band patterns (Figure 2).
Two additional isolates with a different antibi-
ogram pattern had different banding patterns.
Subtyping of M. tuberculosis strains was per-
formed (11) by analyzing DNA located between
two copies of repetitive sequence IS6110. A 10-ml
sample of the extracted DNA was amplified in a
reaction mixture containing 0.5 pM of each of the
four primers (Ris1, Ris2, Pntb1, and Pntb2), 200
UM DNTPs, 50 mM Tris-HCL, 50 mM KCL (pH
8.8), 2.5 mM MgC12, 0.1% Triton x-100, and 0.5%
Taq polymerase. The samples were denatured by
incubation at 95oC for 10 min and amplified by 30
cycles of denaturation at 94oC for 1 min, primer
ali gn men tat56 oCfor2min,andprimerextension
at72
oC for1min.Theamplificationproductswere
analyzed by electrophoresis in 2% agarose gel
stained with ethidium bromide and observed with
an ultraviolet transilluminator.
HIV-infected patients hospitalized on the HIV-
dedicated ward between September 15, 1991, and
December31,1994,whohadTBdiagnosedin1994
with a known drug-susceptibility pattern were
included in a case-control study. Case patients’
isolates were resistant to isoniazid, rifampin,
streptomycin, and ethambutol; control patients’
isolates were sensitive to the same antimicrobial
drugs.
A time-person line diagram was prepared for
each of the case patients and control patients,
including all hospitalization dates,wardandroom
number, potentially infectious days, and possible
daysexposedtoinfectivepatients.Prioradmission
wasdefinedasalladmissionstotheHIV-dedicated
ward since the MDRTB patient was diagnosed
(9/15/91) until the end of the period (12/31/94). TB
patients were classified as “potentially infective”
from the 2 week-period before sputum or culture
results were positive for M. tuberculosis until the
time sputum results were negative or the patient
died.TB-negative patients were classified as “pos-
sibly exposed” if they were hospitalized on the
HIV-dedicated ward during the time a potentially
infective patient was also present, beginning on
September 15,1991,until 2 weeks before TB diag-
nosis.
Thirty-five patients (18 with cases and 17 con-
trols) met the established study case/control defi-
nition.Casepatientsandcontrolpatientswerenot
significantlydifferentwithrespecttoage,sex,HIV
risk factors,interval between HIV and TB diagno-
ses or count of CD4 lymphocytes at the time of TB
diagnosis (Table 2).
BeforethehospitalizationduringwhichTBwas
diagnosed, 76.4% of the case-patients had been
hospitalized on the HIV-dedicated ward of the
hospitalversus23.5%ofcontrolpatients(OR=7.8
[1.4,50.5]) (Table 3). Of the five case patients with
no prior hospitalization, three were family mem-
bers of previously hospitalized HIV-infected pa-
tients who had visited the HIV ward frequently
during the outbreak period.
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Figure 1. Hospital outbreak, Madrid, Spain, 1995.
*1995 data are for first 6 months only.
*All strains of resistance pattern HSER (isoniazid, streptomycin,
ethambutol, rifampin) had similar DNA subtyping.
Figure 2. Evolution of MDRTB strain* over time,
hospital outbreak, Madrid, Spain, 1995.
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respect to possible exposure to a potentially infec-
tive wardmate beginning on 9/15/91 until 2 weeks
p r i o rt ot h ed i a g n o s i so fT B .C a s ep a t i e n t sw e r e
more likely to have been exposed to potentially
infective wardmates (72.2% with a median of 26.4
days) than control patients (41.2% with a median
of 7.6 days). When we stratified possible ward
exposure by days (0 days vs. 1 to 30 days vs. 30
days), we observed a dose-response effect,and the
chi-square for linear trend was statistically sig-
nificant (Table 3). Case patients were more likely
to die during their initial hospitalization for
MDRTB(94.4%) than were control patients
(29.4%) during their hospitalization for TB (OR
= 40.8 [3.6,1842]) (Table 3).
A TB screening clinic visit was offered to all
hospital employees after the outbreak was identi-
fied. Of the 591 active employees, 565 (95.6%)
participated. Of these, 288 (51%) had not partici-
pated in previous hospital employee screening
programsconductedin1990and1994.Theoverall
prevalence of TB infection among participating
employeeswas450(80%)of565;only115(20%)of
the current employees tested were tuberculin-
negative.
Employees currently working at the hospital,
who had a documented negative (< 6 mm) tuber-
culin test between January 1993 and June 1995
were eligible for this skin test conversion study.
Many of the employees had received BCG vaccine.
For those who had not received BCG vaccine, con-
version was defined as an induration of 10 mm or
greater with a change of at least 6 mm of indura-
tionsincethelastnegativetuberculintest(12).For
BCG vaccinees, conversion was defined as a 15-
mm induration change since the last negative
(< 6 mm) skin test.
Employees were defined as occupationally ex-
posedif they workedinparts of the hospitalwhere
exposure to patients or M. tuberculosis was likely
(the HIV-dedicated ward, HIV outpatient clinic,
radiology unit, the mycobacteriology
laboratory,and the internal medicine
ward). Employees were asked to
quantify the cumulative number of
months spent in these high-risk
areas, regardless of their usual place
of work, during the 30-month study
period.
According to the Mantoux tech-
nique, 2 tuberculin units of purified
protein derivative (PPD) tuberculin
RT-23wereadministered intheante-
rior forearm of the screened employ-
ees, and the results were read within
48 to 72 h. Of the participants, 92
(16.3%) were eligible for the conver-
sion study. The incidence of conver-
sion during the 30-month period was
24 of 92 (26%). Employees who had
occupational exposure to high-risk
areas had higher conversion rates
than employees who did not have oc-
cupational exposure to high-risk ar-
eas (RR = 5.0 [2.7,9.6]) (Table 4). The
conversion had a dose-response ef-
fect,that is,the more months the per-
son is occupationally exposed to high
risk-areas,thehighertheriskforcon-
version.
This is the first nosocomially trans-
mitted MDRTB outbreak reported in
Table 2.Population characteristics:case control study
Case patients (%) Control patients (%)
Variable n = 18 n = 17 OR (95% CI)
a
Mean age (yr) 34.4 35.2 p =0 . 3 0
b
Male sex 13 (72.2) 14 (82.3) 1.8 (0.3-12.1)
IVDU 11 (61.1) 11 (64.7) 1.2 (0.2-6.7)
Interval HIV to TB 1403 1293 p =0 . 7 9
b
diagnosis in days
CD4 lymphocyte 112.9 199.5 p =0 . 3 0
b
count, median
a OR (95% CI) = odds ratio (95% confidence intervals);Fisher’s Exact Test.
b p value for analysis of variance (ANOVA).IVDU = intravenous drug user.
Table 3.Variables associated with MDRTB
Case patients (%) Control patients (%)
Variable n = 18 n = 17 OR (95% CI)
a
Prior admission
to HIV ward
Yes 13 (76.4) 5 (29.4) 6.2 (1.2-37.2)
No 5 (23.6) 12 (70.6)
Possible ward
exposure days
None 5 (27.8) 10 (58.8) 1.0
1-30 6 (33.3) 5 (29.4) 2.4
30 7 (38.9) 2 (11.8) 7.0, p =0 . 0 3
b
Outcome
Death 17 (94.4) 5 (29.4) 40.8 (3.6-1842)
Discharge 1 (5.6) 12 (70.6)
aOR (95% CI) = odds ratio (95% confidence intervals);Fisher’s Exact Test.
b Chi-square for linear trend.
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Kingdom (13) and Italy, is among the first in
Europe.Its characteristics are similar to the other
reported outbreaks on that it occurred in an HIV-
dedicated ward among non-foreign-born patients
who had not been treated for TB; it had a high
mortality rate within 3 months of onset during
whichmycobacterialaboratorysurveillancerecog-
nized similar antibiogram resistant patterns; and
identification of MDRTB isolates was followed by
DNA subtyping, which confirmed that the same
strain was responsible for the outbreak. Risk fac-
tors identified include admission to the HIV-dedi-
cated ward and more “possible exposure” days to
potentially infective wardmates;additionally,skin
test conversion rates among employees were di-
rectly related to working in high risk areas of the
hospital. The consistency of these findings with
those reported in similar outbreaks and the fact
that the same isolate was cultured over an exten-
sive period among many different patients on a
hospital ward without proper room isolation tech-
niques support the conclusion that nosocomial
transmission was the leading cause of the out-
break.
CDC’s recommended guidelines for hospital TB
prevention and control (14) were not fully imple-
mented in the hospital. Acid-fast bacilli room iso-
lation techniques were not in place; moreover, no
ventilation system was available to provide nega-
tive pressure to prevent bacilli from passing from
t h eM D R T Bp a t i e n t s ’r o o m st ot h eh a l l w a yo rt o
provide the six air interchanges per hour recom-
mended for removing bacilli from room air. Surgi-
cal masks used in the HIV-dedicated ward during
the outbreak as protective masks are not
recommended for this purpose be-
cause of filtering and facial sealing
problems. Observational visits to
the HIV-dedicated ward revealed
that MDRTB patients without
masks were walking, talking, and
smoking in the halls and in the
lounge next to the unprotected pa-
tients, families, and staff.
Complete follow-up of employees
is anessentialcomponentofa hospi-
tal control program (14). Because
80% of the employees in this out-
break were tuberculin-positive,
chest radiographs became animpor-
tant component for disease screen-
ing;yearly surveillance of the tuberculin-negative
employees willhelp determineiftheinterventions
in place to prevent future outbreaks have worked
in this setting.
Once the case-control study findings were ana-
lyzed,a TB control committee was established.All
MDRTB patients were placed in a separate area
of the hospital.Hospital staff were informedabout
the outbreak and alerted about future possible
cases and the patient management and treatment
schemes. The mycobacteria laboratory expanded
t h ea n t i b i o g r a ms e r v i c et oi n c l u d ea l ls e c o n d - l i n e
antibiotics used by the hospital clinicians. Clini-
cians have elaborated a treatment flow chart for
MDRTB patients.Masks that fulfilled the sealage
and filtering criteria (15) were purchased, and
mask use was aggressively implemented. An em-
ployee health clinic was also instituted, with a
prophylaxisandchestX-rayfollow-upprogramfor
the 410 infected employees, along with a comput-
erized follow-up surveillance system which in-
cluded all employees graded by occupational risk
category. Plans were made to screen tuberculin-
negative employees every 3 months to identify
those who had recently seroconverted. Family,
community members and wardmates of all pa-
tients whose MDRTB had been diagnosed within
the previous 6 months were notified of their risk
and were scheduled for follow-up evaluations.The
HIV-dedicated ward will be transformed into an
acid-fast bacilli isolation zone, with an exclusive
ventilation system that provides 11 individual
rooms,each with 12 air interchanges per hour and
negative pressure relative to the hallway.
Health officials in Europe need to be updated
about this emerging problem, especially in areas
Table 4.Employee tuberculin screening conversion study results
Convertors (%) Nonconvertors (%)
Variable n = 24 n = 68 RR (95% Cl)
Occupational
exposure to
high-risk areas
Yes 14 (70.0) 6 (30.0) 5.0 (2.7, 9.6)
No 10 (13.9) 62 (86.1)
Months exposed
in high-risk areas OR
b
0 6 (10.7) 50 (89.3) 1.0
1-6 4 (28.6) 10 (71.4) 3.3
7-36 14 (63.6) 8 (36.4) 14.6, p <0 . 0 1
aRR (95% CI) relative risk (95% confidence intervals).
b Chi-square for linear trend.
Dispatches
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TB control and prevention measures (16,17)
should be implemented by all general community
hospitalsinSpain,especiallythosewithHIV-dedi-
cated wards in areas where TB is prevalent. TB
surveillance of health care employees is necessary
to identify emerging problems as wellas toprotect
employees, patients, and visitors.
John V. Rullán M.D.,* Dionisio Herrera, M.D.,*
Rosa Cano, M.D.,* Victoria Moreno, M.D.,
† Pere
Godoy, M.D.,* Enrique F. Peiró, M.D.,* Juan
Castell, M.D.,* Consuelo Ibañez, M.D.,* Arturo
Ortega, M.D.,
† Leopoldo Sánchez Agudo, M.D.,
†
and Francisco Pozo, M.D.
‡
Instituto de Salud Carlos III, Ministerio de Sanidad y
Consumo: *Programa de Epidemiología Aplicada de
Campo-Centro Nacional de Epidemiología;
†Centro
Nacional de Investigación Clínica y Medicina
Preventiva;
‡Subdirección General de Salud, Madrid,
Spain
Drs. Herrera, Peiró, Castell, and Godoy have received a
scholarship from the Fondo de Investigación Sanitaria del
Instituto de Salud Carlos III during their 2-year epidemiologic
training period in the Field Epidemiology Training Program
(Programa de Epidemiología Aplicada de Campo).
Acknowledgments
We thank the staff of the Center for Clinical Investiga-
tion and Preventive Medicine of the Instituto de Salud
Carlos III for their collaboration in this investigation; in
particular, staff from the following departments: Admini-
stration, Respiratory Diseases, Infectious Diseases, Nurs-
ing, and the Mycobacteriology Laboratory. For the
employee tuberculin study, we thank Drs. Rafael Rey, and
Dura;LeopoldoSanchezAgudo;MargaritaMuñozArcañiz;
Consuelo Yubero Higuera; Concepción Gonzalez de la
Calle; Lucia Martin Gadea; and Pilar Fuertes Rodrigues
for their collaboration.We acknowledge Dr. Jack Crawford
and staff from the Division of Bacterial and Mycotic Dis-
eases, National Center for Infectious Diseases, CDC, for
their collaboration as reference laboratory for DNA sub-
typing analysis; Dr. Daniel Fishbein for editing the manu-
script; and Dr. Rafael Rey Durán for providing us with the
1990 and 1994 data set of the hospital employees tubercu-
lin test screening. We thank Luis Dorado for his graphics
collaboration.
References
1. Kent JH. The epidemiology of multidrug-resistant
tuberculosis intheUnitedStates.Med ClinNorthAm
1993;77:1391-1409.
2. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of
multidrug-resistant tuberculosis among hospitalized
patients with the acquired immunodeficiency syn-
drome. N Engl J Med 1992;326:1514-21.
3. Beck-Sague C,Dooley SW,Hutton MD,et al.Hospital
outbreak of multidrug-resistant Mycobacterium tu-
berculosis infections: factors in transmission to staff
and HIV-infected patients. JAMA 1992;268:1280-6.
4. Pearson ML, Jereb JA, Frieden TR, et al. Nosocomial
transmission of multidrug-resistant Mycobacterium
tuberculosis: a risk to patients and health care work-
ers. Ann Intern Med 1992;117:191-6.
5. Fischl MA, Uttamchandani RB, Daikos GL, et al. An
outbreak of tuberculosis caused by multiple-drug re-
sistant tubercle bacilli among patients with HIV in-
fection. Ann Intern Med 1992;117:177-83.
6. Dooley SW, Villarino ME, Lawrence M, et al. Noso-
comial transmission of tuberculosis in a hospital unit
for HlV-infected patients. JAMA 1992;267:2632-4.
7. CentersforDiseaseControl.Nosocomialtransmission
of multidrug-resistant tuberculosis among HIV-in-
fected persons—Florida and New York, 1988-1991.
MMWR 1991;40:585-91.
8. Ausina V,Riutort N,Viñado B,et al.Prospective study
of drug-resistant tuberculosis in a Spanish urban
population including patients at risk for HIV infec-
tion. Eur J Microbiol Infect Dis 1995;14:105-10.
9. WHO-EC Collaborating Centres on AIDS. AIDS Sur-
veillance in Europe-European Centre for the
epidemiologicalmonitoringofAIDS.QuarterlyReport
#45; March 1995.
10. Boletín Epidemiológico de la Comunidad de Madrid
1995. Mayo #5, Vol 4. Informe: Morbilidad por Enfer-
medades de Declaración Obligatoria, 1994.
11. Friedman CR, Stoecle MY, Johnson WD, Riley LW.
Double-repetitive-element PCRmethodforsubtyping
M. tuberculosis clinical isolates. J Clin Microbiol
1995;33:1383-4.
12. Grupo de Trabajo sobre Tuberculosis. Consenso na-
cional para el control de la tuberculosis en España.
Med Clin (Barc) 1992;98:24-31.
13. Communicable Disease Report. Outbreak of hospital
acquired multidrug resistant tuberculosis. United
Kingdom PHLS Cornmunicable Disease Surveillance
Centre Weekly 1995.
14. Centers for Disease Control and Prevention. Guide-
lines for preventing the transmission of Mycobac-
terium tuberculosis in health-care facilities, 1994.
MMWR 1994;43 (No. RR-13).
15. Lilienfeld, AM, Lilienfeld DE. Foundations of
epidemiology. 2nd ed. Oxford, UK: Oxford University
Press, 1980;292-5.
16. Maloney SA, Pearson ML, Gordon MT, et al. Efficacy
of control measures in preventing nosocomial trans-
mission of multidrug-resistant tuberculosis to pa-
tients and health care workers. Ann Intern Med
1995;122:90-5.
17. Wenger PN, Otten J, Breeden A, et al. Control of
nosocomial transmission of multidrugresistantMyco-
bacterium tuberculosis among healthcare workers
and HIV-infected patients. Lancet 1995;345:235-40.
Dispatches
Vol. 2, No. 2 —April-June 1996 129 Emerging Infectious Diseases